Thomas J Scriba

List of Publications by Year
in descending order

227 papers	15,465 citations	19608 61 h-index	22764 112 g-index
254 all docs	254 docs citations	254 times ranked	14254 citing authors

#	Article	IF	Citations
1	Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet, The, 2013, 381, 1021-1028.	6.3	903
2	Identifying specificity groups in the T cell receptor repertoire. Nature, 2017, 547, 94-98.	13.7	825
3	A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet, The, 2016, 387, 2312-2322.	6.3	678
4	Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. New England Journal of Medicine, 2018, 379, 138-149.	13.9	532
5	Immunological biomarkers of tuberculosis. Nature Reviews Immunology, 2011, 11, 343-354.	10.6	455
6	Specific T Cell Frequency and Cytokine Expression Profile Do Not Correlate with Protection against Tuberculosis after Bacillus Calmette-GuÃ©rin Vaccination of Newborns. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1073-1079.	2.5	386
7	Distinct, Specific IL-17- and IL-22-Producing CD4+ T Cell Subsets Contribute to the Human Anti-Mycobacterial Immune Response. Journal of Immunology, 2008, 180, 1962-1970.	0.4	378
8	Final Analysis of a Trial of M72/AS01_E Vaccine to Prevent Tuberculosis. New England Journal of Medicine, 2019, 381, 2429-2439.	13.9	350
9	Phase 2b Controlled Trial of M72/AS01_EVaccine to Prevent Tuberculosis. New England Journal of Medicine, 2018, 379, 1621-1634.	13.9	319
10	T cells and adaptive immunity to Mycobacterium tuberculosis in humans. Immunological Reviews, 2015, 264, 74-87.	2.8	305
11	Analyzing the Mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening. Nature Biotechnology, 2020, 38, 1194-1202.	9.4	282
12	Human MAIT and CD8Î±Î± cells develop from a pool of type-17 precommitted CD8+ T cells. Blood, 2012, 119, 422-433.	0.6	239
13	Bacillus Calmette-Guèrin Vaccination of Human Newborns Induces T Cells with Complex Cytokine and Phenotypic Profiles. Journal of Immunology, 2008, 180, 3569-3577.	0.4	236
14	T-cell activation is an immune correlate of risk in BCG vaccinated infants. Nature Communications, 2016, 7, 11290.	5.8	236
15	COMPASS identifies T-cell subsets correlated with clinical outcomes. Nature Biotechnology, 2015, 33, 610-616.	9.4	232
16	Four-Gene Pan-African Blood Signature Predicts Progression to Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1198-1208.	2.5	217
17	Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease. PLoS Pathogens, 2017, 13, e1006687.	2.1	193
18	A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes. Nature, 2018, 560, 644-648.	13.7	184

#	Article	IF	Citations
19	First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine, 2015, 33, 4130-4140.	1.7	183
20	Modified vaccinia Ankaraâ€expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4⁺ T cells. European Journal of Immunology, 2010, 40, 279-290.	1.6	171
21	Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes. Journal of Immunological Methods, 2015, 422, 28-34.	0.6	171
22	Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. European Respiratory Journal, 2016, 48, 1751-1763.	3.1	165
23	Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis. Cell Host and Microbe, 2017, 21, 695-706.e5.	5.1	164
24	Host blood RNA signatures predict the outcome of tuberculosis treatment. Tuberculosis, 2017, 107, 48-58.	0.8	156
25	Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South Africa. Journal of Infectious Diseases, 2008, 198, 544-552.	1.9	155
26	Polyfunctional CD4+ T Cells As Targets for Tuberculosis Vaccination. Frontiers in Immunology, 2017, 8, 1262.	2.2	154
27	Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferation. Journal of Immunological Methods, 2010, 362, 43-50.	0.6	140
28	HIV-1 Infection Impairs the Bronchoalveolar T-Cell Response to Mycobacteria. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 1262-1270.	2.5	138
29	Tuberculosis Vaccines and Prevention of Infection. Microbiology and Molecular Biology Reviews, 2014, 78, 650-671.	2.9	133
30	Metabolite changes in blood predict the onset of tuberculosis. Nature Communications, 2018, 9, 5208.	5.8	129
31	A Quantitative Analysis of Complexity of Human Pathogen-Specific CD4 T Cell Responses in Healthy M. tuberculosis Infected South Africans. PLoS Pathogens, 2016, 12, e1005760.	2.1	128
32	Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 638-648.	2.5	124
33	Safety and immunogenicity of the novel tuberculosis vaccine ID93â€˜+â€˜GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. Lancet Respiratory Medicine,the, 2018, 6, 287-298.	5.2	122
34	Bacillus Calmetteâ€“GuÃ©rin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses. Journal of Immunology, 2016, 197, 1100-1110.	0.4	121
35	Longitudinal Changes in CD4+ T-Cell Memory Responses Induced by BCG Vaccination of Newborns. Journal of Infectious Diseases, 2013, 207, 1084-1094.	1.9	120
36	Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response. Vaccine, 2009, 27, 5488-5495.	1.7	117

#	Article	IF	Citations
37	Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting. Vaccine, 2015, 33, 4025-4034.	1.7	110
38	Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine,the, 2017, 5, 282-290.	5.2	110
39	The Dynamics of QuantiFERON-TB Gold In-Tube Conversion and Reversion in a Cohort of South African Adolescents. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 584-591.	2.5	108
40	Human Immunology of Tuberculosis. Microbiology Spectrum, 2017, 5, .	1.2	101
41	Moving tuberculosis vaccines from theory to practice. Nature Reviews Immunology, 2019, 19, 550-562.	10.6	101
42	Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial. Lancet Respiratory Medicine,the, 2019, 7, 757-770.	5.2	92
43	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. Scientific Reports, 2020, 10, 8629.	1.6	90
44	HIVâ€1 Infection in Infants Severely Impairs the Immune Response Induced by Bacille Calmetteâ€GuÃ©rin Vaccine. Journal of Infectious Diseases, 2009, 199, 982-990.	1.9	88
45	Ultrasensitive Detection and Phenotyping of CD4+ T Cells with Optimized HLA Class II Tetramer Staining. Journal of Immunology, 2005, 175, 6334-6343.	0.4	85
46	S100A8/A9 regulates CD11b expression and neutrophil recruitment during chronic tuberculosis. Journal of Clinical Investigation, 2020, 130, 3098-3112.	3.9	85
47	Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. Lancet Infectious Diseases, The, 2021, 21, 354-365.	4.6	84
48	St John's Wort (Hypericum perforatum L.) Photomedicine: Hypericin-Photodynamic Therapy Induces Metastatic Melanoma Cell Death. PLoS ONE, 2014, 9, e103762.	1.1	83
49	The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses. PLoS ONE, 2014, 9, e87340.	1.1	79
50	A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates. PLoS Pathogens, 2019, 15, e1007643.	2.1	79
51	A Phase IIa Trial of the New Tuberculosis Vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosisâ€“infected Adults. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 769-778.	2.5	78
52	A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population. Immunogenetics, 2013, 65, 357-370.	1.2	77
53	Dose-Finding Study of the Novel Tuberculosis Vaccine, MVA85A, in Healthy BCG-Vaccinated Infants. Journal of Infectious Diseases, 2011, 203, 1832-1843.	1.9	75
54	Combined Use of Mycobacterium tuberculosisâ€“Specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of Active Tuberculosis. Clinical Infectious Diseases, 2015, 60, 432-437.	2.9	75

#	Article	IF	Citations
55	Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 220-231.	2.5	75
56	Can we predict tuberculosis cure? What tools are available?. European Respiratory Journal, 2018, 52, 1801089.	3.1	73
57	Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study. PLoS Medicine, 2019, 16, e1002781.	3.9	72
58	Predominance of interleukin-22 over interleukin-17 at the site of disease in human tuberculosis. Tuberculosis, 2011, 91, 587-593.	0.8	71
59	The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial. Vaccine, 2015, 33, 3592-3599.	1.7	71
60	Tuberculosis Vaccine Development: Progress in Clinical Evaluation. Clinical Microbiology Reviews, 2019, 33, .	5.7	70
61	Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry. Journal of Immunological Methods, 2015, 417, 22-33.	0.6	68
62	Select sequencing of clonally expanded CD8⁺T cells reveals limits to clonal expansion. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8995-9001.	3.3	68
63	Differential gene expression of activating FcÎ³ receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. Clinical Microbiology and Infection, 2014, 20, O230-O238.	2.8	65
64	T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation. European Respiratory Journal, 2018, 51, 1800153.	3.1	65
65	Tracking Virus-Specific CD4+ T Cells during and after Acute Hepatitis C Virus Infection. PLoS ONE, 2007, 2, e649.	1.1	65
66	Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease. Vaccine, 2010, 29, 51-57.	1.7	64
67	Impaired IFN-Î³-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. Aids, 2006, 20, 821-829.	1.0	63
68	Single nucleotide polymorphisms in toll-like receptor 6 are associated with altered lipopeptide- and mycobacteria-induced interleukin-6 secretion. Genes and Immunity, 2010, 11, 561-572.	2.2	58
69	Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis. Seminars in Immunology, 2020, 50, 101431.	2.7	57
70	Human newborn bacille Calmetteâ€“GuÃ©rin vaccination and risk of tuberculosis disease: a case-control study. BMC Medicine, 2016, 14, 76.	2.3	55
71	MR1-Independent Activation of Human Mucosal-Associated Invariant T Cells by Mycobacteria. Journal of Immunology, 2019, 203, 2917-2927.	0.4	55
72	Immune correlates of tuberculosis disease and risk translate across species. Science Translational Medicine, 2020, 12, .	5.8	52

#	Article	IF	Citations
73	Safety and Immunogenicity of H1/IC31Â®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm3: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial. PLoS ONE, 2014, 9, e114602.	1.1	52
74	A Population Response Analysis Approach To Assign Class II HLA-Epitope Restrictions. Journal of Immunology, 2015, 194, 6164-6176.	0.4	51
75	CD4 and CD8 T-Cell Responses to Mycobacterial Antigens in African Children. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 120-129.	2.5	50
76	Varicella Zosterâ€“Specific CD4+Foxp3+ T Cells Accumulate after Cutaneous Antigen Challenge in Humans. Journal of Immunology, 2013, 190, 977-986.	0.4	50
77	Comparison of CyTOF assays across sites: Results of a six-center pilot study. Journal of Immunological Methods, 2018, 453, 37-43.	0.6	50
78	Diagnostic performance of an optimized transcriptomic signature of risk of tuberculosis in cryopreserved peripheral blood mononuclear cells. Tuberculosis, 2018, 108, 124-126.	0.8	49
79	A comparison of IFNÎ³ detection methods used in tuberculosis vaccine trials. Tuberculosis, 2008, 88, 631-640.	0.8	47
80	The impact of HIV exposure and maternal Mycobacterium tuberculosis infection on infant immune responses to bacille Calmette-GuÃ©rin vaccination. Aids, 2015, 29, 155-165.	1.0	47
81	A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants. Vaccine, 2015, 33, 2944-2954.	1.7	47
82	Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy. Frontiers in Microbiology, 2019, 10, 1441.	1.5	46
83	Safety and immunogenicity of the adjunct therapeutic vaccine ID93â€ˆ+â€ˆGLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Respiratory Medicine,the, 2021, 9, 373-386.	5.2	46
84	Diagnostic Accuracy of the Cepheid 3-gene Host Response Fingerstick Blood Test in a Prospective, Multi-site Study: Interim Results. Clinical Infectious Diseases, 2022, 74, 2136-2141.	2.9	46
85	Relationship between female genital tract infections, mucosal interleukinâ€17 production and local T helper type 17 cells. Immunology, 2015, 146, 557-567.	2.0	45
86	Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines. Journal of Infectious Diseases, 2016, 214, 659-664.	1.9	45
87	TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development. Frontiers in Immunology, 2017, 8, 1203.	2.2	44
88	Functional, Antigen-Specific Stem Cell Memory (TSCM) CD4+ T Cells Are Induced by Human Mycobacterium tuberculosis Infection. Frontiers in Immunology, 2018, 9, 324.	2.2	44
89	HIV-1â€“specific CD4+ T lymphocyte turnover and activation increase upon viral rebound. Journal of Clinical Investigation, 2005, 115, 443-450.	3.9	44
90	Fetal public VÎ³9VÎ´2 T cells expand and gain potent cytotoxic functions early after birth. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18638-18648.	3.3	43

#	Article	IF	Citations
91	A Serum Circulating miRNA Signature for Short-Term Risk of Progression to Active Tuberculosis Among Household Contacts. Frontiers in Immunology, 2018, 9, 661.	2.2	42
92	Cytomegalovirus infection is a risk factor for tuberculosis disease in infants. JCI Insight, 2019, 4, .	2.3	42
93	The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses. Vaccine, 2014, 32, 5908-5917.	1.7	41
94	The Cross-Species Mycobacterial Growth Inhibition Assay (MGIA) Project, 2010â€“2014. Vaccine Journal, 2017, 24, .	3.2	41
95	Immunometabolic Signatures Predict Risk of Progression to Active Tuberculosis and Disease Outcome. Frontiers in Immunology, 2019, 10, 527.	2.2	40
96	Real-Time Investigation of Tuberculosis Transmission: Developing the Respiratory Aerosol Sampling Chamber (RASC). PLoS ONE, 2016, 11, e0146658.	1.1	40
97	The TB-specific CD4+ T cell immune repertoire in both cynomolgus and rhesus macaques largely overlap with humans. Tuberculosis, 2015, 95, 722-735.	0.8	39
98	Differential Recognition ofMycobacterium tuberculosisâ€“Specific Epitopes as a Function of Tuberculosis Disease History. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 772-781.	2.5	39
99	Performance of diagnostic and predictive host blood transcriptomic signatures for Tuberculosis disease: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0237574.	1.1	39
100	HIVâ€1 infection alters CD4⁺ memory Tâ€cell phenotype at the site of disease in extrapulmonary tuberculosis. European Journal of Immunology, 2012, 42, 147-157.	1.6	38
101	A Functional Toll-Interacting Protein Variant Is Associated with Bacillus Calmette-GuÃ©rinâ€“Specific Immune Responses and Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 502-511.	2.5	38
102	Effect of Isoniazid Therapy for Latent TB Infection on QuantiFERON-TB Gold In-Tube Responses in Adults With Positive Tuberculin Skin Test Results in a High TB Incidence Area. Chest, 2014, 145, 612-617.	0.4	37
103	A Glucuronoxylomannan-Associated Immune Signature, Characterized by Monocyte Deactivation and an Increased Interleukin 10 Level, Is a Predictor of Death in Cryptococcal Meningitis. Journal of Infectious Diseases, 2016, 213, 1725-1734.	1.9	37
104	Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. Tuberculosis, 2013, 93, 143-149.	0.8	35
105	A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents. Tuberculosis, 2015, 95, 713-721.	0.8	35
106	H1:IC31 vaccination is safe and induces long-lived TNF-Î±+IL-2+CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial. Vaccine, 2017, 35, 132-141.	1.7	34
107	Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. The Lancet Global Health, 2021, 9, e841-e853.	2.9	34
108	Maturation of Innate Responses to Mycobacteria over the First Nine Months of Life. Journal of Immunology, 2014, 192, 4833-4843.	0.4	33

#	Article	IF	Citations
109	Differential DNA methylation of potassium channel KCa3.1 and immune signalling pathways is associated with infant immune responses following BCG vaccination. Scientific Reports, 2018, 8, 13086.	1.6	33
110	HLA-DR Marks Recently Divided Antigen-Specific Effector CD4 T Cells in Active Tuberculosis Patients. Journal of Immunology, 2021, 207, 523-533.	0.4	33
111	Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial. Clinical Infectious Diseases, 2018, 66, 554-563.	2.9	32
112	Precise Identification of a Human Immunodeficiency Virus Type 1 Antigen Processing Mutant. Journal of Virology, 2007, 81, 2031-2038.	1.5	30
113	A Diverse Lipid Antigenâ€“Specific TCR Repertoire Is Clonally Expanded during Active Tuberculosis. Journal of Immunology, 2018, 201, 888-896.	0.4	30
114	HIV-1â€“specific CD4+ T lymphocyte turnover and activation increase upon viral rebound. Journal of Clinical Investigation, 2005, 115, 443-450.	3.9	30
115	Distinct T-Cell Responses When BCG Vaccination Is Delayed From Birth to 6 Weeks of Age in Ugandan Infants. Journal of Infectious Diseases, 2014, 209, 887-897.	1.9	29
116	Mixed Th1 and Th2 Mycobacterium tuberculosis-specific CD4 T cell responses in patients with active pulmonary tuberculosis from Tanzania. PLoS Neglected Tropical Diseases, 2017, 11, e0005817.	1.3	29
117	Significantly skewed memory CD8+ T cell subsets in HIV-1 infected infants during the first year of life. Clinical Immunology, 2009, 130, 280-289.	1.4	28
118	Protein kinase C-delta (PKCÎ´), a marker of inflammation and tuberculosis disease progression in humans, is important for optimal macrophage killing effector functions and survival in mice. Mucosal Immunology, 2018, 11, 496-511.	2.7	28
119	Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. Tuberculosis, 2018, 109, 61-68.	0.8	28
120	T Cell Responses against Mycobacterial Lipids and Proteins Are Poorly Correlated in South African Adolescents. Journal of Immunology, 2015, 195, 4595-4603.	0.4	27
121	Heterologous vaccination against human tuberculosis modulates antigenâ€specific <scp>CD</scp>4⁺<scp>T</scp>â€cell function. European Journal of Immunology, 2013, 43, 2409-2420.	1.6	26
122	Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1171-1180.	2.5	26
123	Antigen-Specific T-Cell Activation Distinguishes between Recent and Remote Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1556-1565.	2.5	25
124	Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response. BMC Infectious Diseases, 2014, 14, 314.	1.3	24
125	The Role of Clinical Symptoms in the Diagnosis of Intrathoracic Tuberculosis in Young Children. Pediatric Infectious Disease Journal, 2015, 34, 1157-1162.	1.1	23
126	Differential leukocyte counting and immunophenotyping in cryopreserved ex vivo whole blood. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 157-165.	1.1	23

#	Article	IF	Citations
127	The CSF Immune Response in HIV-1â€“Associated Cryptococcal Meningitis: Macrophage Activation, Correlates of Disease Severity, and Effect of Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 299-307.	0.9	23
128	CD1b Tetramers Identify T Cells that Recognize Natural and Synthetic Diacylated Sulfoglycolipids from Mycobacterium tuberculosis. Cell Chemical Biology, 2018, 25, 392-402.e14.	2.5	23
129	Characterization and Phylogenetic Analysis of South African HIV-1 Subtype C Accessory Genes. AIDS Research and Human Retroviruses, 2001, 17, 775-781.	0.5	22
130	Anti-coreceptor antibodies profoundly affect staining with peptide-MHC class I and class II tetramers. European Journal of Immunology, 2006, 36, 1847-1855.	1.6	22
131	Validation of a CD1b tetramer assay for studies of human mycobacterial infection or vaccination. Journal of Immunological Methods, 2018, 458, 44-52.	0.6	22
132	Allelic resolution NGS HLA typing of Class I and Class II loci and haplotypes in Cape Town, South Africa. Human Immunology, 2018, 79, 839-847.	1.2	22
133	Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial. Gates Open Research, 2017, 1, 9.	2.0	22
134	TheStaphyloccous aureusEap Protein Activates Expression of Proinflammatory Cytokines. Infection and Immunity, 2008, 76, 2164-2168.	1.0	21
135	Identification of Antigens Specific to Non-Tuberculous Mycobacteria: The Mce Family of Proteins as a Target of T Cell Immune Responses. PLoS ONE, 2011, 6, e26434.	1.1	20
136	Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A. BMC Infectious Diseases, 2014, 14, 660.	1.3	20
137	Relationship between chemokine receptor expression, chemokine levels and HIV â€1 replication in the lungs of persons exposed to M ycobacterium tuberculosis. European Journal of Immunology, 2013, 43, 540-549.	1.6	19
138	Batf2 differentially regulates tissue immunopathology in Type 1 and Type 2 diseases. Mucosal Immunology, 2019, 12, 390-402.	2.7	19
139	Peripheral Blood Mucosal-Associated Invariant T Cells in Tuberculosis Patients and Healthy Mycobacterium tuberculosis-Exposed Controls. Journal of Infectious Diseases, 2020, 222, 995-1007.	1.9	19
140	Evaluation of XpertÂ® MTB/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial. PLoS ONE, 2015, 10, e0141623.	1.1	19
141	Effects of BCG vaccination on donor unrestricted T cells in two prospective cohort studies. EBioMedicine, 2022, 76, 103839.	2.7	19
142	Immune Profiling Enables Stratification of Patients With Active Tuberculosis Disease or Mycobacteriu m tuberculosis Infection. Clinical Infectious Diseases, 2021, 73, e3398-e3408.	2.9	18
143	T Cells Specific for a Mycobacterial Glycolipid Expand after Intravenous Bacillus Calmetteâ€“GuÃ©rin Vaccination. Journal of Immunology, 2021, 206, 1240-1250.	0.4	18
144	A randomized clinical trial in adults and newborns in South Africa to compare the safety and immunogenicity of bacille Calmette-GuÃ©rin (BCG) vaccine administration via a disposable-syringe jet injector to conventional technique with needle and syringe. Vaccine, 2015, 33, 4719-4726.	1.7	17

#	Article	IF	Citations
145	Immune profiling of Mycobacterium tuberculosis-specific T cells in recent and remote infection. EBioMedicine, 2021, 64, 103233.	2.7	17
146	Transcriptomics for child and adolescent tuberculosis*. Immunological Reviews, 2022, 309, 97-122.	2.8	17
147	Functional analysis of novel SLC11A1 (NRAMP1) promoter variants in susceptibility to HIV-1. Journal of Medical Genetics, 2004, 41, e49-e49.	1.5	16
148	Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences. Vaccine, 2005, 23, 1158-1169.	1.7	16
149	Optimization of a whole blood intracellular cytokine assay for measuring innate cell responses to mycobacteria. Journal of Immunological Methods, 2012, 376, 79-88.	0.6	16
150	The SIGLEC14 null allele is associated with Mycobacterium tuberculosis- and BCG-induced clinical and immunologic outcomes. Tuberculosis, 2017, 104, 38-45.	0.8	16
151	Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making. Npj Vaccines, 2018, 3, 36.	2.9	16
152	Elevated IgG Responses in Infants Are Associated With Reduced Prevalence of Mycobacterium tuberculosis Infection. Frontiers in Immunology, 2018, 9, 1529.	2.2	16
153	Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A. Vaccine Journal, 2014, 21, 1005-1011.	3.2	15
154	Impact of Xpert MTB/RIF rollout on management of tuberculosis in a South African community. South African Medical Journal, 2017, 107, 1078.	0.2	15
155	Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1463-1472.	2.5	15
156	Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR. Communications Medicine, 2022, 2, .	1.9	15
157	Characterization of the South African HIV Type 1 Subtype C Complete 5â€² Long Terminal Repeat,nef,and Regulatory Genes. AIDS Research and Human Retroviruses, 2002, 18, 149-159.	0.5	14
158	Novel Evolutionary Analyses of Full-Length HIV Type 1 Subtype C Molecular Clones from Cape Town, South Africa. AIDS Research and Human Retroviruses, 2002, 18, 1327-1332.	0.5	14
159	Application of a whole blood mycobacterial growth inhibition assay to study immunity against Mycobacterium tuberculosis in a high tuberculosis burden population. PLoS ONE, 2017, 12, e0184563.	1.1	14
160	Postnatal Expansion, Maturation, and Functionality of MR1T Cells in Humans. Frontiers in Immunology, 2020, 11, 556695.	2.2	14
161	Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines. Communications Biology, 2020, 3, 563.	2.0	14
162	BCG and New Preventive Tuberculosis Vaccines: Implications for Healthcare Workers. Clinical Infectious Diseases, 2016, 62, S262-S267.	2.9	13

#	Article	IF	Citations
163	Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy. Scientific Reports, 2019, 9, 11126.	1.6	13
164	A Review and Proposed Approach to the Neutrophilic Dermatoses of Childhood. Pediatric Dermatology, 2015, 32, 437-446.	0.5	12
165	Mycobacterium tuberculosis-specific CD4 T cells are the principal source of IFN-Î³ in QuantiFERON assays in healthy persons. Tuberculosis, 2015, 95, 350-351.	0.8	12
166	Predicting tuberculosis risk â€“ Authorsâ€™ reply. Lancet, The, 2016, 388, 2233-2234.	6.3	12
167	Toll-like receptor chaperone HSP90B1 and the immune response to Mycobacteria. PLoS ONE, 2018, 13, e0208940.	1.1	12
168	Integrating Non-human Primate, Human, and Mathematical Studies to Determine the Influence of BCG Timing on H56 Vaccine Outcomes. Frontiers in Microbiology, 2018, 9, 1734.	1.5	12
169	Diagnostic Accuracy of Early Secretory Antigenic Target-6â€“Free Interferon-gamma Release Assay Compared to QuantiFERON-TB Gold In-tube. Clinical Infectious Diseases, 2019, 69, 1724-1730.	2.9	12
170	Diagnostic accuracy of plasma kynurenine/tryptophan ratio, measured by enzyme-linked immunosorbent assay, for pulmonary tuberculosis. International Journal of Infectious Diseases, 2020, 99, 441-448.	1.5	12
171	Multinomial modelling of TB/HIV co-infection yields a robust predictive signature and generates hypotheses about the HIV+TB+ disease state. PLoS ONE, 2019, 14, e0219322.	1.1	11
172	Effect of Inflammatory Cytokines/Chemokines on Pulmonary Tuberculosis Culture Conversion and Disease Severity in HIV-Infected and -Uninfected Individuals From South Africa. Frontiers in Immunology, 2021, 12, 641065.	2.2	11
173	Immunological protection against tuberculosis. South African Medical Journal, 2007, 97, 973-7.	0.2	11
174	African-based CCR5 single-nucleotide polymorphism associated with HIV-1 disease progression. Aids, 2002, 16, 2229-2231.	1.0	10
175	Identification of key peptide-specific CD4+T cell responses to human cytomegalovirus: implications for tracking antiviral populations. Clinical and Experimental Immunology, 2006, 146, 203-210.	1.1	10
176	Use of Peptide-Major Histocompatibility Complex Tetramer Technology To Study Interactions betweenStaphylococcus aureusProteins and Human Cells. Infection and Immunity, 2007, 75, 5711-5715.	1.0	10
177	Plasma Type I IFN Protein Concentrations in Human Tuberculosis. Frontiers in Cellular and Infection Microbiology, 2019, 9, 296.	1.8	10
178	Molecular Detection of Airborne Mycobacterium tuberculosis in South African High Schools. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 350-356.	2.5	10
179	Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children. Pediatric Infectious Disease Journal, 2015, 34, 1218-1222.	1.1	9
180	Temporal trends in the prevalence of Mycobacterium tuberculosis infection in South African adolescents. International Journal of Tuberculosis and Lung Disease, 2019, 23, 571-578.	0.6	9

#	Article	IF	Citations
181	Mycobacterium tuberculosis-Specific T Cell Functional, Memory, and Activation Profiles in QuantiFERON-Reverters Are Consistent With Controlled Infection. Frontiers in Immunology, 2021, 12, 712480.	2.2	8
182	CD4 and CD8 co-receptors modulate functional avidity of CD1b-restricted T cells. Nature Communications, 2022, 13, 78.	5.8	8
183	Time to Symptom Resolution in Young Children Treated for Pulmonary Tuberculosis. Pediatric Infectious Disease Journal, 2014, 33, 1226-1230.	1.1	7
184	A novel blood test for tuberculosis prevention and treatment. South African Medical Journal, 2016, 107, 4.	0.2	7
185	Flow Cytometry To Assess Cerebrospinal Fluid Fungal Burden in Cryptococcal Meningitis. Journal of Clinical Microbiology, 2016, 54, 802-804.	1.8	7
186	Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 159 individuals from the Worcester region of the Western Cape province of South Africa. Human Immunology, 2018, 79, 143-144.	1.2	7
187	Performance of host blood transcriptomic signatures for diagnosing and predicting progression to tuberculosis disease in HIV-negative adults and adolescents: a systematic review protocol. BMJ Open, 2019, 9, e026612.	0.8	7
188	Inflammatory Determinants of Differential Tuberculosis Risk in Pre-Adolescent Children and Young Adults. Frontiers in Immunology, 2021, 12, 639965.	2.2	7
189	A novel blood test for tuberculosis prevention and treatment. South African Medical Journal, 2016, 107, 4.	0.2	7
190	Clinical predictors of pulmonary tuberculosis among South African adults with HIV. EClinicalMedicine, 2022, 45, 101328.	3.2	7
191	Human immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4+ T cell decline following short-course treatment at primary HIV-1 infection. Clinical and Experimental Immunology, 2008, 152, 532-537.	1.1	6
192	Individual-level factors associated with variation in mycobacterial-specific immune response: Gender and previous BCG vaccination status. Tuberculosis, 2016, 96, 37-43.	0.8	6
193	Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination. International Journal of Tuberculosis and Lung Disease, 2017, 21, 778-783.	0.6	6
194	Human Immunology of Tuberculosis. , 2017, , 213-237.		6
195	Comparison of haematology and biochemistry parameters in healthy South African infants with laboratory reference intervals. Tropical Medicine and International Health, 2018, 23, 63-68.	1.0	6
196	Blood transcriptional signatures for tuberculosis testing. Lancet Respiratory Medicine,the, 2020, 8, 330-331.	5.2	6
197	Immune Phenotype and Functionality of Mtb-Specific T-Cells in HIV/TB Co-Infected Patients on Antiretroviral Treatment. Pathogens, 2020, 9, 180.	1.2	6
198	Renewing the Fight Against TB with an Old Vaccine. Cell, 2020, 180, 829-831.	13.5	6

#	Article	IF	Citations
199	REL and BHLHE40 Variants Are Associated with IL-12 and IL-10 Responses and Tuberculosis Risk. Journal of Immunology, 2022, 208, 1352-1361.	0.4	6
200	Prospects for a vaccine to prevent HIV-related tuberculosis. Current Opinion in HIV and AIDS, 2018, 13, 522-527.	1.5	5
201	BCG Vaccination of Infants Confers Mycobacterium tuberculosis Strain-Specific Immune Responses by Leukocytes. ACS Infectious Diseases, 2020, 6, 3141-3146.	1.8	5
202	Regional changes in tuberculosis disease burden among adolescents inÂSouth AfricaÂ(2005â€“2015). PLoS ONE, 2020, 15, e0235206.	1.1	5
203	Headway made towards biosignatures for incipient tuberculosis. Lancet Respiratory Medicine,the, 2020, 8, 328-330.	5.2	5
204	Host blood transcriptomic biomarkers of tuberculosis disease in people living with HIV: a systematic review protocol. BMJ Open, 2021, 11, e048623.	0.8	5
205	The impact of blood transcriptomic biomarker targeted tuberculosis preventive therapy in people living with HIV: a mathematical modelling study. BMC Medicine, 2021, 19, 252.	2.3	4
206	Durable Expansion of TCR-Î´ Meta-Clonotypes After BCG Revaccination in Humans. Frontiers in Immunology, 2022, 13, 834757.	2.2	4
207	Targeted Gene Expression Profiling of Human Myeloid Cells From Blood and Lung Compartments of Patients With Tuberculosis and Other Lung Diseases. Frontiers in Immunology, 2022, 13, 839747.	2.2	4
208	SATVI - after 10 years closing in on a new and better vaccine to prevent tuberculosis. South African Medical Journal, 2012, 102, 438.	0.2	3
209	Prevalence of latent TB infection and TB disease among adolescents in high TB burden countries in Africa: a systematic review protocol. BMJ Open, 2017, 7, e014609.	0.8	3
210	Long-lasting tuberculous pleurisy. European Respiratory Journal, 2017, 49, 1700356.	3.1	3
211	The effect of antiretroviral treatment on selected genes in whole blood from HIV-infected adults sensitised by Mycobacterium tuberculosis. PLoS ONE, 2018, 13, e0209516.	1.1	3
212	Protection against tuberculosis by mucosal BCG administration. Nature Medicine, 2019, 25, 199-201.	15.2	3
213	Host transcriptomic signatures of tuberculosis can predict immune reconstitution inflammatory syndrome in HIV patients. European Journal of Immunology, 2022, , .	1.6	3
214	Evaluation of a transcriptomic signature of tuberculosis risk in combination with an interferon gamma release assay: A diagnostic test accuracy study. EClinicalMedicine, 2022, 47, 101396.	3.2	3
215	Non-volatile organic compounds in exhaled breath particles correspond to active tuberculosis. Scientific Reports, 2022, 12, 7919.	1.6	3
216	Teaching advanced flow cytometry in Africa: 10 years of lessons learned. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2016, 89, 971-974.	1.1	2

#	Article	IF	Citations
217	The effect of host factors on discriminatory performance of a transcriptomic signature of tuberculosis risk. EBioMedicine, 2022, 77, 103886.	2.7	2
218	Mycobacterium tuberculosis infection, immune activation, and risk of HIV acquisition. PLoS ONE, 2022, 17, e0267729.	1.1	2
219	T cell responses to Mycobacterium indicus pranii immunotherapy and adjunctive glucocorticoid therapy in tuberculous pericarditis. Vaccine: X, 2022, 11, 100177.	0.9	2
220	Diagnostic Challenge of Tuberculosis Heterogeneity. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 286-296.	0.8	1
221	Multidimensional analysis of immune responses identified biomarkers of recent Mycobacterium tuberculosis infection. PLoS Computational Biology, 2021, 17, e1009197.	1.5	1
222	The effect of new Mycobacterium tuberculosis infection on the sensitivity of prognostic TB signatures. International Journal of Tuberculosis and Lung Disease, 2021, 25, 1001-1005.	0.6	1
223	P098 HLA haplotype diversity in Cape Town, South Africa. Human Immunology, 2016, 77, 110.	1.2	0
224	POLICY-DRIVEN INTERVENTIONS: TUBERCULOSIS. BMJ Global Health, 2017, 2, A4.1-A4.	2.0	0
225	120. A Randomized Double-blind Trial Assessing the Efficacy of M72/AS01E Vaccine Against Pulmonary Tuberculosis Disease in Adults With Latent Mycobacterium tuberculosis Infection. Open Forum Infectious Diseases, 2018, 5, S5-S6.	0.4	0
226	Dramatically Impaired BCGâ€specific Immune Response in HIV+ Infants. FASEB Journal, 2008, 22, 496-496.	0.2	0
227	A simple assay to quantify mycobacterial lipid antigen-specific T cell receptors in human tissues and blood. PLoS Neglected Tropical Diseases, 2021, 15, e0010018.	1.3	0